| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
J Thorac Cardiovasc Surg 1997;114:210-217
© 1997 Mosby, Inc.
GENERAL THORACIC SURGERY |
Received for publication August 29, 1996; revisions requested Feb. 13, 1997; revisions received March 12, 1997; accepted for publication March 13, 1997. Address for reprints: John Wong, PhD, FRACS, FACS, Department of Surgery, The University of Hong Kong, Queen Mary Hospital, Pokfulam Rd., Hong Kong.
Abstract
Objective: This study investigated the role of preoperative chemotherapy in squamous cell cancer of the esophagus.Methods: A prospective randomized trial was undertaken in 147 patients: 74 received preoperative chemotherapy comprising cisplatin and 5-fluorouracil and 73 had surgical therapy alone. End points were cancer and therapy-related deaths.Results: Sixty-six patients (89%) in the chemotherapy group underwent resection compared with 69 (95%) in the control group (p = not significant). Of the 60 patients who had resection after completing the chemotherapy program, 35 (58%) had a significant response, of whom four (6.7%) had a complete pathologic response. Postoperative mortality rates were 8.3% and 8.7% in the chemotherapy and control groups, respectively (p = not significant). Significant downstaging was evident with chemotherapy; curative resections were possible in 67% of these patients compared with 35% in the control group (p = 0.0003). T3 and T4 tumors were found in 67% and 91% of the chemotherapy and control groups, respectively (p = 0.0002). The respective figures for N1 disease were 70% and 88% (p = 0.009). An intent-to-treat analysis of survival showed no significant difference between the two groups. Median survivals were 16.8 and 13 months, respectively (p = 0.17). Of those who completed the chemotherapy and resection, responders fared better than control patients. Median survivals were 42.2 months and 13.8 months, respectively (p = 0.003). Median survival (8.3 months) was worse for nonresponders than for control patients (p = 0.03). The recurrence pattern suggested a significant reduction in locoregional disease with chemotherapy.Conclusions: Preoperative chemotherapy was safe and resulted in significant downstaging and an increased likelihood of curative resection. Survival was not better than that in the surgery-alone group, but responders did fare better than nonresponders. J Thorac Cardiovasc Surg 1997;114:210-7
This article has been cited by other articles:
|
|
 |
|
  T. YOSHIDA, T. MIYOSHI, J.-I. SEIKE, H. YAMAI, H. TAKECHI, Y. YUASA, and A. TANGOKU Gene Expression Changes in a Chemoresistant Model with Human Esophageal Cancer Xenografts Using cDNA Microarray Anticancer Res, April 1, 2009; 29(4): 1163 - 1168. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. F. Bruzzi, R. F. Munden, M. T. Truong, E. M. Marom, B. S. Sabloff, G. W. Gladish, R. B. Iyer, T.-S. Pan, H. A. Macapinlac, and J. J. Erasmus PET/CT of Esophageal Cancer: Its Role in Clinical Management RadioGraphics, November 1, 2007; 27(6): 1635 - 1652. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. Graham, F. M. Shrive, W. A. Ghali, B. J. Manns, S. C. Grondin, R. J. Finley, and J. Clifton Defining the Optimal Treatment of Locally Advanced Esophageal Cancer: A Systematic Review and Decision Analysis Ann. Thorac. Surg., April 1, 2007; 83(4): 1257 - 1264. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. W. Gee and D. W. Rattner Management of Gastroesophageal Tumors Oncologist, February 1, 2007; 12(2): 175 - 185. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Lagarde, F. J.W. ten Kate, J. B. Reitsma, O. R.C. Busch, and J. J. B. van Lanschot Prognostic Factors in Adenocarcinoma of the Esophagus or Gastroesophageal Junction J. Clin. Oncol., September 10, 2006; 24(26): 4347 - 4355. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Lee, K.-E. Lee, Y.-H. Im, W. K. Kang, K. Park, K. Kim, and Y. M. Shim Adjuvant Chemotherapy with 5-Fluorouracil and Cisplatin in Lymph Node-Positive Thoracic Esophageal Squamous Cell Carcinoma Ann. Thorac. Surg., October 1, 2005; 80(4): 1170 - 1175. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. de Manzoni, C. Pedrazzani, E. Laterza, F. Pasini, A. Grandinetti, M. Bernini, A. Ruzzenente, G. Zerman, A. Tomezzoli, and C. Cordiano Induction Chemoradiotherapy for Squamous Cell Carcinoma of the Thoracic Esophagus: Impact of Increased Dosage on Long-Term Results Ann. Thorac. Surg., October 1, 2005; 80(4): 1176 - 1183. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Hu, R. Li, L. Sun, and Y. Ni Comparison of influence of esophageal carcinoma operations on pulmonary function Eur. J. Cardiothorac. Surg., July 1, 2005; 28(1): 16 - 18. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.-B. Moore Joshi, Y. Shirota, K. D. Danenberg, D. H. Conlon, D. S. Salonga, J. E. Herndon II, P. V. Danenberg, and D. H. Harpole Jr. High Gene Expression of TS1, GSTP1, and ERCC1 Are Risk Factors for Survival in Patients Treated with Trimodality Therapy for Esophageal Cancer Clin. Cancer Res., March 15, 2005; 11(6): 2215 - 2221. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Hu, R. Li, L. Sun, and Y. Ni Influence of esophageal carcinoma operations on gastroesophageal reflux Ann. Thorac. Surg., July 1, 2004; 78(1): 298 - 302. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F Fiorica, D Di Bona, F Schepis, A Licata, L Shahied, A Venturi, A M Falchi, A Craxi, and C Camma Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis Gut, July 1, 2004; 53(7): 925 - 930. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. C. Malaisrie, B. Untch, G. V. Aranha, N. Mohideen, A. Hantel, and J. Pickleman Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Cancer: Experience at a Single Institution Arch Surg, May 1, 2004; 139(5): 532 - 539. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Koshy, N. Esiashvilli, J. C. Landry, C. R. Thomas Jr., and R. H. Matthews Multiple Management Modalities in Esophageal Cancer: Combined Modality Management Approaches Oncologist, April 1, 2004; 9(2): 147 - 159. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. A. Wieder, B. L.D.M. Brucher, F. Zimmermann, K. Becker, F. Lordick, A. Beer, M. Schwaiger, U. Fink, J. R. Siewert, H. J. Stein, et al. Time Course of Tumor Metabolic Activity During Chemoradiotherapy of Esophageal Squamous Cell Carcinoma and Response to Treatment J. Clin. Oncol., March 1, 2004; 22(5): 900 - 908. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Kostakoglu and S. J. Goldsmith PET in the Assessment of Therapy Response in Patients with Carcinoma of the Head and Neck and of the Esophagus J. Nucl. Med., January 1, 2004; 45(1): 56 - 68. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Ando, T. Iizuka, H. Ide, K. Ishida, M. Shinoda, T. Nishimaki, W. Takiyama, H. Watanabe, K. Isono, N. Aoyama, et al. Surgery Plus Chemotherapy Compared With Surgery Alone for Localized Squamous Cell Carcinoma of the Thoracic Esophagus: A Japan Clinical Oncology Group Study--JCOG9204 J. Clin. Oncol., December 15, 2003; 21(24): 4592 - 4596. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. S. Mao, M. Suntharalingam, and M. J. Krasna Management of late distant metastases after trimodality therapy for esophageal cancer Ann. Thorac. Surg., November 1, 2003; 76(5): 1742 - 1743. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. W. Rice, D. J. Adelstein, M. A. Chidel, L. A. Rybicki, M. M. DeCamp, S. C. Murthy, and E. H. Blackstone Benefit of postoperative adjuvant chemoradiotherapy in locoregionally advanced esophageal carcinoma J. Thorac. Cardiovasc. Surg., November 1, 2003; 126(5): 1590 - 1596. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. S. Keresztes, J. L. Port, M. W. Pasmantier, R. J. Korst, and N. K. Altorki Preoperative chemotherapy for esophageal cancer with paclitaxel and carboplatin: Results of a phase II trial J. Thorac. Cardiovasc. Surg., November 1, 2003; 126(5): 1603 - 1608. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. B. Polee, H. W. Tilanus, F. A. L. M. Eskens, R. Hoekstra, M. E. L. Van der Burg, P. D. Siersema, G. Stoter, and A. Van der Gaast Phase II study of neo-adjuvant chemotherapy with paclitaxel and cisplatin given every 2 weeks for patients with a resectable squamous cell carcinoma of the esophagus Ann. Onc., August 1, 2003; 14(8): 1253 - 1257. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Hagen and T. R. DeMeester Staging of esophageal carcinoma J. Thorac. Cardiovasc. Surg., May 1, 2003; 125(5): 988 - 991. [Full Text] [PDF]
|
|
|
|
|
|
A. D. Roth, A. S. Allal, M.-A. Brundler, R. de Peyer, B. Mermillod, P. Morel, and O. Huber Neoadjuvant radiochemotherapy for locally advanced gastric cancer: a phase I-II study Ann. Onc., January 1, 2003; 14(1): 110 - 115. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. Bains, A. Stojadinovic, B. Minsky, V. Rusch, A. Turnbull, R. Korst, R. Ginsberg, D. P. Kelsen, and D. H. Ilson A phase II trial of preoperative combined-modality therapy for localized esophageal carcinoma: Initial results J. Thorac. Cardiovasc. Surg., August 1, 2002; 124(2): 270 - 277. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. Doty, J. D. Salazar, A. A. Forastiere, E. I. Heath, L. Kleinberg, and R. F. Heitmiller Postesophagectomy morbidity, mortality, and length of hospital stay after preoperative chemoradiation therapy Ann. Thorac. Surg., July 1, 2002; 74(1): 227 - 231. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. W.C. Entwistle III and M. Goldberg Multimodality therapy for resectable cancer of the thoracic esophagus Ann. Thorac. Surg., March 1, 2002; 73(3): 1009 - 1015. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. L. Aquino, K. S. Lee, and S. H. Kim Invited Commentary Authors' Response RadioGraphics, September 1, 2001; 21(5): 1138 - 1140. [Full Text] [PDF]
|
|
|
|
|
|
W. A. Weber, K. Ott, K. Becker, H.-J. Dittler, H. Helmberger, N. E. Avril, G. Meisetschlager, R. Busch, J.-R. Siewert, M. Schwaiger, et al. Prediction of Response to Preoperative Chemotherapy in Adenocarcinomas of the Esophagogastric Junction by Metabolic Imaging J. Clin. Oncol., June 15, 2001; 19(12): 3058 - 3065. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Jiao, M. J. Krasna, J. Sonett, Z. Gamliel, M. Suntharalingam, A. Doyle, and B. Greenwald Pretreatment surgical lymph node staging predicts results of trimodality therapy in esophageal cancer Eur. J. Cardiothorac. Surg., June 1, 2001; 19(6): 880 - 886. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. W. Rice, E. H. Blackstone, D. J. Adelstein, G. Zuccaro Jr, J. J. Vargo, J. R. Goldblum, L. A. Rybicki, S. C. Murthy, and M. M. DeCamp N1 esophageal carcinoma: The importance of staging and downstaging J. Thorac. Cardiovasc. Surg., March 1, 2001; 121(3): 454 - 464. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. H. Harpole Jr., M.-B. Moore, J. E. Herndon II, T. Aloia, T. A. D’Amico, T. Sporn, A. Parr, I. Linoila, and C. Allegra The Prognostic Value of Molecular Marker Analysis in Patients Treated with Trimodality Therapy for Esophageal Cancer Clin. Cancer Res., March 1, 2001; 7(3): 562 - 569. [Abstract] [Full Text]
|
|
|
|
|
|
D. J. Adelstein, T. W. Rice, L. A. Rybicki, M. A. Larto, J. Ciezki, J. Saxton, M. DeCamp, J. J. Vargo, J. A. Dumot, and G. Zuccaro Does Paclitaxel Improve the Chemoradiotherapy of Locoregionally Advanced Esophageal Cancer? A Nonrandomized Comparison With Fluorouracil-Based Therapy J. Clin. Oncol., May 10, 2000; 18(10): 2032 - 2039. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. D. Wright, U. Fink, H. J. Stein, J. Fleeth, F. Begemann, A. Y. Chang, D. Kelsen, T. Pajak, and R. Ginsberg Treatment of Esophageal Cancer N. Engl. J. Med., May 27, 1999; 340(21): 1685 - 1687. [Full Text]
|
|
|
|
|
|
C. E. Reed Surgical Management of Esophageal Carcinoma Oncologist, April 1, 1999; 4(2): 95 - 105. [Abstract] [Full Text]
|
|
|
|
|
|
C. Alexiou, D. Beggs, F. D. Salama, E. T. Brackenbury, and W. E. Morgan Surgery for esophageal cancer in elderly patients: The view from Nottingham J. Thorac. Cardiovasc. Surg., October 1, 1998; 116(4): 545 - 553. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Lerut Esophageal surgery at the end of the millennium J. Thorac. Cardiovasc. Surg., July 1, 1998; 116(1): 1 - 20. [Full Text]
|
|
|
|
|
|
D. B. Skinner Editorial on combined therapy for squamous cell carcinoma of the esophagus J. Thorac. Cardiovasc. Surg., August 1, 1997; 114(2): 203 - 204. [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |
